Recalled butter sold in 10 states receives risk warning: FDA - WGN-TV
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Recalled butter sold in 10 states receives risk warning: FDA - WGN-TV" is generating significant coverage in the Business category, with 14 articles from 13 distinct sources tracked by PULSE so far.
Outlets currently covering the story include NBC 5 Chicago, KOMO, WSB-TV and ABC7 Los Angeles. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 18d ago.
Quick answers
Why is "Recalled butter sold in 10 states receives risk warning: FDA - WGN-TV" trending?
Because 13 independent news sources published 14 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (14)
- Mold, E. coli and yeast prompts recall of plant-based butter sold in Illinois NBC 5 Chicago · 21d ago
- Butter sold in 10 states recalled over possible E. coli, yeast and mold contamination KOMO · 21d ago
- Recall alert: Butter recalled in 10 states WSB-TV · 21d ago
- Butter recalled: Miyoko's plant-based product recalled after E. coli, mold concerns ABC7 Los Angeles · 21d ago
- Plant-based butter recalled over yeast, mold, E. coli concerns USA Today · 21d ago
- Check your fridge for recalled butter sold in Iowa The Des Moines Register · 21d ago
- Butter Recalled Due to Yeast, Mold, and E. Coli Contamination—What to Know Martha Stewart · 21d ago
- Plant-based butter recalled over yeast, mold and E.coli concerns receives FDA risk classification ABC News - Breaking News, Latest News and Videos · 21d ago
- Butter recalled over yeast, mold and E.coli concerns gets FDA risk classification Yahoo · 21d ago
- Recalled butter sold in 10 states receives risk warning: FDA The Hill · 21d ago
- Butter sold in 10 states recalled over possible E. coli, yeast and mold contamination KOMO · 21d ago
- FDA recalls butter brand over potential illness caused by E.coli, mold and yeast New York Post · 21d ago
- Butter Recalled for Yeast, Mold, and E. Coli Contamination—Here’s What to Know EatingWell · 21d ago
- Recalled butter sold in 10 states receives risk warning: FDA WGN-TV · 21d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.